11/10/2014 | PP | GTx negotiates $43.41 million private placement of common share units
|
3/4/2014 | PP | GTx will conduct $21.27 million private placement of its common stock
|
6/23/2011 | PP | GTx to raise $47.5 million via public offering of common stock
|
6/22/2011 | PP | GTX plans public offering of its common stock through Citi, Jefferies
|
2/2/2009 | SS | Investor Jack Schuler reports 5.5% stake in GTx
|
12/31/2008 | CVHY | GTx files $100 million shelf registration
|
11/6/2007 | PP | Market Commentary: Enhanced Oil stops at C$16.71 million; Kodiak looks at C$40 million; GTx plans $30 million
|
11/6/2007 | PP | New Issue: GTx to raise $30 million from stock placement with Merck
|
12/14/2006 | PP | Market Commentary: Linn Energy pockets $360 million from PIPE; Geron gears up to close $40 million stock offering
|
12/13/2006 | PP | New Issue: GTx secures $60.79 million from direct placement of stock
|
12/13/2006 | PP | Market Commentary: GTx to close $60.8 million direct stock sale; EntreMed to close $17.16 million direct placement
|
11/7/2006 | BT | GTx to announce ostarine proof-of-concept data, selected indication in late November
|
11/2/2006 | BT | GTX: license fee from Ipsen boosts cash to $70.9 million, will fund operations to 2008
|
9/7/2006 | BT | Ipsen and GTx partner on European rights to cancer drug Acapodene
|
9/5/2006 | BT | GTx to continue phase 3 trials of Acapodene for prostate cancer
|
7/20/2006 | BT | GTx completes enrollment of phase 2 ostarine trial
|
6/22/2006 | BT | GTx: Acapodene reduces side effects of androgen deprivation therapy in prostate cancer
|
4/21/2006 | BT | GTx starts phase 3b extension trial of Acapodene for treatment of androgen deprivation therapy side effects
|
1/31/2006 | BT | GTx, Gen-Probe form agreement to study prostate cancer assay
|
1/19/2006 | BT | GTx continues phase 3 trials of Acapodene for prostate cancer following safety review
|
12/15/2005 | BT | GTx: Analysis shows Acapodene raises bone mineral density in men with prostate cancer
|
10/19/2005 | BT | GTx reaches enrollment goal in phase III Acapodene trial
|
10/14/2005 | BT | GTx greenshoe exercised in full, upping stock offer to 6,325,000 shares
|
10/11/2005 | BT | New Issue: GTx prices upsized 5.5 million shares at $7.80 per share
|
10/10/2005 | BT | GTx revives follow-on sale of 5 million shares, changes bookrunners
|
9/23/2005 | BT | GTx delays follow-on sale of 5 million shares
|
9/23/2005 | BT | Market Commentary: Nektar upsizes home-run convertible, Renovis raves, Acusphere sinks after follow-ons; Cyberonics slips
|
9/22/2005 | BT | Market Commentary: Nektar convertible at bat along with follow-ons from GTx, Renovis; Cyberonics prices wide, closes off
|
9/19/2005 | BT | Market Commentary: Viacell plunges on suspending study; StemCells rises on new filing; Inex drops on note demand
|
9/16/2005 | BT | Market Commentary: Meridian Biosciences slips in spot deal; Myogen, Geron deals show improved reception
|
9/15/2005 | BT | GTx plans follow-on sale of 5 million shares via Goldman Sachs
|
9/15/2005 | BT | Market Commentary: Myogen, Geron follow-ons at bat; ViroPharma up; Advancis almost doubles; GTx launches new deal
|
8/4/2005 | BT | GTx files $100 million stock shelf
|